In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexo AB

www.orexo.com

Latest From Orexo AB

The Many Paths To Biotech CEO

There is no single path toward becoming a CEO. The job requires many different skills, often concurrently: sharp analytical capabilities, strategic thinking, clear communication with multiple audiences, curiosity and perseverance. It demands strong leadership but also humility, and a willingness to acknowledge mistakes and knowledge gaps.

C-Suite Speaks Business Strategies

US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist

US FDA will add boxed warnings to insomnia drugs, bringing it in line with other regulators, even as a study in JAMA Internal Medicine study indicates that national drug authorities often disagree more broadly over when to issue safety advisories.
Drug Safety FDA

Defusing US Opioid Crisis Offers Orexo "Strong Growth Potential" Says CEO

The CEO of Swedish addiction and pain specialist Orexo tells Scrip its top drug Zubsolv will grow strongly in coming years to address the opioid crisis in the US, and that revenues will be further boosted by novel pipeline therapies likely to be commercialized in coming years.

Business Strategies Commercial

Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

Deals Business Strategies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Diabact
  • Orexo Pharmaceuticals AB
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Orexo AB
  • Senior Management
  • Nikolaj Sorensen, CEO
    Michael Sumner, PhD, CMO
    Jesper Lind, COO
  • Contact Info
  • Orexo AB
    Phone: (46) 18 780 88 00
    P.O. Box 303 Uppsala, SE 751 05
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register